Full text
Earnings transcript
Read the complete earnings call transcript.
TXG
10x Genomics, Inc.
$22.33
0.28
(1.27%)
[ms_data_label text=’Delayed data’]
| Exchange: | NASDAQ |
| Market Cap: | 2.853B |
| Shares Outstanding: | 11.588M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Healthcare Information Services | |||||
| CEO: | Serge Saxonov | |||||
| Full Time Employees: | 1306 | |||||
| Address: |
| |||||
| Website: | https://www.10xgenomics.com |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 618,727 | 610,785 | 642,823 |
| Gross Profit | 409,313 | 414,482 | 443,881 |
| EBITDA | -205,111 | -133,988 | -110,885 |
| Operating Income | -265,329 | -194,559 | -110,885 |
| Net Income | -255,099 | -182,627 | -43,544 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 965,143 | 918,636 | 1,041,365 |
| Total Liabilities | 224,100 | 208,502 | 245,039 |
| Total Stockholders Equity | 741,043 | 710,134 | 796,326 |
| Total Debt | 95,370 | 82,613 | 157,737 |
| Cash and Cash Equivalents | 359,284 | 344,067 | 473,966 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -15,197 | 6,664 | 136,050 |
| Capital Expenditure | -49,524 | -12,393 | -5,935 |
| Free Cash Flow | -64,721 | -5,729 | 130,115 |
| Net Income | -255,099 | -182,627 | -43,544 |
| Net Change in Cash | 131,931 | -15,217 | 129,899 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 827,987.431 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 873,603.267 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 849,866.667 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -178,621.842 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -169,294.971 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -173,768.523 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | -40,507.535 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | -37,779.255 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | -39,087.881 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 449,300.620 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 474,053.681 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 461,173.209 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | -0.310 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | -0.300 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | -0.320 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 4 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 4 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Innovative Product Portfolio: TXG, operating in the biotechnology industry within the healthcare sector, focuses on cutting-edge genomic solutions as highlighted in the company profile. The description emphasizes its role in enabling advanced research, positioning it as a leader in a niche, high-growth market.
- Strong Revenue Performance: Income statement data indicates consistent revenue growth over recent years, reflecting robust demand for TXG’s products. This aligns with industry trends in biotechnology, where innovation drives market expansion.
- Healthy Liquidity Position: Balance sheet metrics show significant cash and cash equivalents alongside a favorable current ratio (TTM), suggesting TXG has the financial flexibility to fund R&D and operational needs without immediate liquidity concerns.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about TXG valuation
Is 10x Genomics, Inc. (TXG) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for 10x Genomics, Inc. (TXG) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is TXG a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether TXG trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is TXG’s P/E ratio?
You can see TXG’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for TXG?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is TXG a good long-term investment?
Whether TXG fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
TXG
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
1.27
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 6.78 | Year High: | 23.56 | |
| Price Avg 50: | 20.04 | Price Avg 200: | 15.83 | |
| Volume: | 1.277M | Average Volume: | 2.55M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeTXG full analysis
Welcome to MARKETSNAP’s SWOT analysis for 10x Genomics, also known by its ticker TXG. If you’re looking to dive deep into a company that’s making waves in the biotech space, you’ve come to the right place. Today, we’re breaking down the strengths, weaknesses, opportunities, and threats for 10x Genomics, a key player in the life sciences technology industry, to help you make informed decisions for your long-term investment portfolio. So, let’s get started with a quick overview of who they…
